PRODIA

https://www.neurodegenerationresearch.eu/survey/prodia/

Title of study

PRODIA

Acronym for cohort
Name of Principal Investigator - Title

Dr

Name of Principal Investigator - First name

Charlotte

Name of Principal Investigator - Last name

Teunissen

Address of institution -Institution

Vumc

Address of institution - Street address

Boelelaan 1117

Address of institution - City

Amsterdam

Address of institution - Postcode

1081 HV

Country

Netherlands

Website
Contact email

Funding source

ZonMW

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

To identify and validate novel CSF biomarkers for differential diagnosis of dementia, with a pathological relation.

Q2b. What distinguishes this case-control study from other studies?

We identify biomarkers via merging of tissue and CSF proteomics datasets, which is an unique approach.

Q3a. i) Number of publications that involve use of your cohort to date
Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

We expect to identify biomarkers for use in clinical practise for diagnosis of dementia patients.

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

50

Q4a. Study criteria: what is the age range of participants at recruitment? To:

80

Q4b. Study criteria: what are the inclusion criteria?

Amsterdam dementia cohort, so retrospective and biobanked samples of patients with defined clinical diagnosis of dementias.

Q4c. Study criteria: what are the exclusion criteria?
Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?

1-1,000

Q5b. What is the expected number of control participants?

200-500

Q6a. Please describe what measures are used to characterise participants

clinical diagnosis, MMSE

Q6b. Are there additional measures for participants with the clinical disorder?

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If YES please specify
Q7. What is the study design?

Prospective cohort

Q8. Are your cases matched by

Age| Sex

Q9a. Does your study includes a specialised subset of control participants?

Yes

Q9b. If your study includes a specialised subset of control participants please describe

individuals with subjective memory complaints

Q10a. Is data collection for this study

Data collection ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - intend to apply for funding

Q11. Are data collected

Through links to other records or registers(Amsterdam dementia cohort)

Q12. Is there a system in place to enable re-contact with patients for future studies?

Yes (participants have given permission to be re-contacted via the PIs)

Q13a. Please give information on data stored in a database (1)

Data summarised in database

% Available

100

Q13a. Please give information on data stored in a database (2)

No

% Available

Q13a. Please give information on data stored in a database (3)

No

% Available
Q13a. Please give information on data stored in a database (4)

No

% Available
Q13a. Please give information on data stored in a database (5)

Yes

% Available

100

Please specify language used

Access

% Available

100

Q13b. Please give information on how data is held as individual records

No

% Available
Q14a. Are data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource

Q15. What data sharing policy is specified as a condition of use?

No policy exists

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below

Living donors: blood| Living donors: blood derivatives| Living donors: DNA| Living donors: cerebro-spinal fluid

Q16b. ii) In what form are tissues/samples/DNA supplied?

Primary Samples: Stabilised samples (frozen or fixed)| Secondary samples: plasma| Secondary samples: DNA

Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Yes

Q17. Is information on biological characteristics available to other groups?

Yes, for all the cohort

Types:
Case Control Studies

Member States:
Netherlands

Diseases:
Alzheimer's disease & other dementias

Years:
2016

Database Categories:
N/A

Database Tags:
N/A